Pancreatic Enzyme Replacement Therapy

Phase 3Small molecule

Pancreatic Enzyme Replacement Therapy is one of 46 small molecule programs targeting Acute Pancreatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

PancreatitisNot yet recruiting

Acute PancreatitisPreclinical

Active, not recruiting

PancreatitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

33 competitors in Pancreatitis

#DrugCompanyPhaseTrials

Indocin

CCosette Pharmaceuticals, Inc.

Approved

23 2

Voltaren

Novartis

Approved

5 3

Cysteine Hydrochloride

Novartis

Approved

1 4

Doribax

Shionogi

Approved

—5

Avycaz

PPhiladelphia Eye Associates

Approved

1 6

Nitrostat

VViatris Specialty LLC

Approved

1 7

Imuran

LLegacy Health System

Approved

1 8

Esbriet

LLegacy Health System

Approved

—9

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—10

Trental

VValidus Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Pancreatitis

NCT07211568

Q3 2028

ApprovedRecruiting

Chronic Pancreatitis

NCT07418593

Clinical

Trials by Indication[1]

Acute Pancreatitis1 trial

Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy

Unknown status·UUnidade Local de Saúde de Coimbra, EPE·N/A·NCT05480241·84 enrolled

Pancreatitis1 trial

PERT in Acute Necrotizing Pancreatitis

Not yet recruiting·—·Phase 3·NCT07211568·188 enrolled

Chronic Pancreatitis1 trial

Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis

Recruiting·AAnna Evans Phillips·Approved·NCT07418593·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pancreatic Enzyme Replacement Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pancreatic Enzyme Replacement Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pancreatic Enzyme Replacement Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unidade Local de Saúde de Coimbra, EPE company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUnidade Local de Saúde de Coimbra, EPE

Pancreatic Enzyme Replacement Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Acute Pancreatitis1 trial

Pancreatitis1 trial

Chronic Pancreatitis1 trial

References

Drug Info

Quick Facts

Related News